Citations

Showing 10 of 108083 citations.

Three-Lobed Donor Left Lungs: Imaging and Clinical Implication in Thoracic Transplantation
Garg, Pankaj , Ahmed, Magdy M. El‐Sayed , Makey, Ian A. , Jacob, Samuel , Garg, Pankaj

Mayo Clinic

Texas Heart Institute Journal | November 28, 2022 | Volume: 49 | Issue: 6 | Pages: No page available

10.14503/thij-22-7860 | PMID 36441543 Get It

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
Ho, Phoebe Joy, Shaughnessy, Paul , Bishop, Michael, Geethakumari, Praveen Ramakrishnan , Ross, Ainsley, Stevens, William B. , Xu, Huansheng, Ma, Anna, Beaussant-Cohen, Sarah , Bachier, Carlos, McGuirk, Joseph P. , Tam, Constantine S. , Kroger, Nicolaus , Riedell, Peter A. , Murthy, Hemant S. , Maakaron, Joseph E. , Waller, Edmund K. , Awan, Farrukh T. , Ghobadi, Armin , Piérola, Ana Alfonso , Dickinson, Michael , Stevens, William, Beaussant, Sarah cohen , Maziarz, Richard Thomas

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10303-10306

10.1182/blood-2022-166432 Get It

Symptomatic myopathies in sarcoidosis: disease spectrum and myxovirus resistance protein A expression
Chompoopong, Pitcha , Skolka, Michael , Ernste, Floranne C. , Milone, Margherita , Skolka, Michael P., Liewluck, T , Chompoopong, Pitcha , Skolka, Michael P , Liewluck, Teerin

Mayo Clinic

Rheumatology | November 28, 2022 | Volume: 62 | Issue: 7 | Pages: 2556-2562

10.1093/rheumatology/keac668 | PMID 36440911 Get It

Abstract Objectives Symptomatic myopathy in sarcoidosis patients is not always due to sarcoid myopathy (ScM). We investigated the clinical and pathological spectrum including myxovirus resistance protein A (MxA) expression among sarcoidosis patients. Methods We reviewed the Mayo Clinic database (May 1980–December 2020) to identify sarcoidosis patients with myopathic symptoms and pathological evidence of myopathy. Results Among 5885 sarcoidosis patients, 21 had symptomatic myopathy. Eight carried a diagnosis of sarcoidosis 5.5 years (median) prior to myopathy onset. Eleven patients had ScM. The remaining had non-sarcoid myopathies (five IBM, one immune-mediated necrotizing myopathy, one non-specific myositis, two non-specific myopathy and one steroid myopathy). Estimated frequency of IBM is 85 per 100 000 sarcoidosis patients. The following features were associated with non-sarcoid myopathies (P < 0.05): (i) predominant finger flexor and quadriceps weakness, (ii) modified Rankin scale (mRS) >2 at time of diagnosis, (iii) creatine kinase >500 U/l, and (iv) absence of intramuscular granulomas. Sarcoplasmic MxA expression was observed in scattered myofibres in three patients, two of whom were tested for DM-specific autoantibodies and were negative. Immunosuppressive therapy led to improvement in mRS ≥1 in 5/10 ScM, none of the five IBM, and 3/3 remaining patients with non-sarcoid myopathies. Discussion Symptomatic myopathy occurred in 0.36% of sarcoidosis. IBM was the second most common cause of myopathies after ScM. Frequency of IBM in sarcoidosis is higher than in the general population. Recognition of features suggestive of alternative aetiologies can guide proper treatment. Our findings of abnormal MxA expression warrant a larger study.
Changes in Abdominal Aortic Aneurysm Size after Endovascular Repair with Zenith, AneuRx, and Custom-made Stent-Grafts
Neuhauser, Beate, Oldenburg, W. Andrew, Hakaim, Albert G.

Mayo Clinic

The American Surgeon | November 28, 2022 | Volume: 70 | Issue: 7 | Pages: 630-634

10.1177/000313480407000714 Get It

The aim of this study was to determine the maximal aneurysm diameter (MAD), the total aneurysm volume (TAV), the intra-aneurysm vascular channel (IAVC), and total thrombus volume (TTV) and compare changes in those parameters during a 12-month time period. In addition, these parameters for three different endovascular grafts were compared. A retrospective review of 42 patients who had undergone endovascular aneurysm repair (EVAR) between July 1999 and March 2001, and without evidence of an endoleak or migration, was performed. The minimum follow-up in this group was 12 months. The three grafts deployed were Dacron-stainless steel bifurcated grafts with suprarenal fixation [Zenith; Cook, Inc. ( n = 14)], Dacron stainless steel aorto uni-iliac grafts with suprarenal fixation [custom-made ( n = 10)], and externally supported Dacron nitinol bifurcated grafts [AneuRx; Medtronic, Inc. ( n = 18)]. Volumetric measurements were obtained from CT images performed preoperatively, at 1 month and 12 months thereafter, using a 3-D Magicview 1000 workstation (Siemens, Inc.). Regardless of the type of endograft, a significant Change in MAD and TAV ( P = 0.008), IAVC ( P = 0.031), and TTV ( P = 0.001) was observed over the 12-month postoperative period. Both maximum diameter and total aneurysm volume appear to reflect accurately successful aneurysm exclusion. We conclude that both two-dimensional, maximal aneurysm diameter and three-dimensional, total aneurysm volume accurately reflect changes in morphology after endovascular aneurysm repair.
Outcomes of Laparoscopic versus Open Appendectomy
Burns, Justin M. , Lincourt, Amy E., Harold, Kristi L., Carbonell, Alfredo M.

Mayo Clinic

The American Surgeon | November 28, 2022 | Volume: 70 | Issue: 9 | Pages: 759-766

10.1177/000313480407000903 Get It

Controversy remains regarding which approach is better, laparoscopic appendectomy (LA) or open appendectomy (OA). A 5-year retrospective review of patients undergoing appendectomy was performed to compare the outcomes of LA and OA using standard statistical methods ( P < 0.05). LA was performed in 207 and OA in 100 patients (conversion 6.7%). Females underwent LA more frequently than males (81.7% vs 51.9%; P = 0.0001). LA patients were older (30.2 years vs 25.7 years; P = 0.03), with no differences in body mass index (BMI) (27.9 kg/m 2 vs 25.5 kg/m 2 ; P = 0.06) or operative times (51.1 minutes vs 51.5 minutes; P = 0.84).’ LA patients required less analgesics (19.2 mg vs 31.5 mg; P = 0.01), and shorter hospital stays (27.2 hours vs 53.1 hours; P = 0.0001). Operating room charges were higher for LA ($3839 vs $2528; P = 0.0001), with no difference in total hospital charges ($8801. vs $9147; P = 0.14). Complications between LA and OA were similar (3.6% vs 8%; P = 0.12). Converted patients were older, required more analgesia, and had higher morbidity, length of stay, and hospital charges. LA is the procedure of choice for appendicitis regardless of age, sex, BMI, or degree of appendiceal inflammation. LA is as safe and quick to perform as OA with lower analgesic requirements, length of stay, and no difference in total charges.
Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis
Thao, Viengneesee , Dholakia, Ruchita, Dwarkasing, Jvalini, Meves, Alexander , Moriarty, James P. , Meves, Alexander , Borah, Bijan J.

Mayo Clinic

International Journal of Dermatology | November 28, 2022 | Volume: 62 | Issue: 1 | Pages: 56-61

10.1111/ijd.16515 | PMID 36440797 Get It

AbstractBackgroundThe Merlin assay for melanoma‐risk assessment has become commercially available to reduce the rate of unnecessary sentinel lymph node biopsies (SLNB) in SLNB‐eligible patients with cutaneous melanoma. Merlin low‐risk patients are recommended to undergo wide local excision (WLE) of the primary tumor, whereas Merlin high‐risk patients are recommended to undergo both SLNB and WLE. Here, we compared the cost of a Merlin testing strategy to that of a no‐testing strategy (usual care) before prescribing SLNB.MethodsWe identified T1 and T2 patients who underwent WLE and SLNB but not completion lymph node dissection between 2007 and 2018. Controls were T1 patients who only underwent WLE. Costs for WLE and SLNB were calculated by converting institutional cost data to standardized Medicare reimbursement rates. We then developed a decision tree to compare the cost of Merlin testing to that of a no‐testing strategy (usual care).ResultsThe average standardized cost of WLE was $2066, whereas the cost of WLE and SLNB was $11,976 based on Medicare rates. At a cost below $7350 for T1b melanoma and $4600 for T1b to T2 melanoma, Merlin testing was cost‐saving compared to a no‐testing strategy (usual care), assuming Medicare reimbursement rates.ConclusionMerlin testing for T1b and T2 melanoma is potentially cost saving depending on the cost of the molecular assay and SLNB reimbursement rates. In addition to being cost saving, Merlin is expected to improve health‐related quality of life.
Unusual and rare cause of abdominal pain: abdominal desmoid fibromatosis masquerading as a postoperative haematoma
Bracamonte, Jesse D., Lodin, Hannah M, Schweda, Denise, Lodin, Hannah

Mayo Clinic

BMJ Case Reports | November 28, 2022 | Volume: 15 | Issue: 11 | Pages: e251873

10.1136/bcr-2022-251873 | PMID 36442908 Get It

Desmoid fibromatosis is a rare connective tissue malignancy. It can occur in a variety of locations, including the abdominal wall, extremities and abdominal cavity. There has been an association with development in a prior surgical scar. Common symptoms can vary depending on the location and can include being painless to having pain at the site, functional impairment and bowel obstruction from intra-abdominal masses. In the following report, we discuss a case in which a patient’s abdominal pain was attributed to a postoperative haematoma based on CT radiographic features; however, further work-up and biopsy yielded desmoid fibromatosis, a rare locally aggressive malignancy.
Headache classification and automatic biomarker extraction from structural MRIs using deep learning
Siddiquee, Md Mahfuzur Rahman , Shah, Jay , Nikolova, Simona , Li, Baojie , Rahman Siddiquee, Md Mahfuzur , Chong, Catherine, Chong, Catherine D. , Dumkrieger, Gina , Wu, Teresa , Schwedt, Todd J.

Mayo Clinic

Brain Communications | November 28, 2022 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcac311 | PMID 36751567 Get It

AbstractData-driven machine-learning methods on neuroimaging (e.g. MRI) are of great interest for the investigation and classification of neurological diseases. However, traditional machine learning requires domain knowledge to delineate the brain regions first, followed by feature extraction from the regions. Compared with this semi-automated approach, recently developed deep learning methods have advantages since they do not require such prior knowledge; instead, deep learning methods can automatically find features that differentiate MRIs from different cohorts. In the present study, we developed a deep learning-based classification pipeline distinguishing brain MRIs of individuals with one of three types of headaches [migraine (n = 95), acute post-traumatic headache (n = 48) and persistent post-traumatic headache (n = 49)] from those of healthy controls (n = 532) and identified the brain regions that most contributed to each classification task. Our pipeline included: (i) data preprocessing; (ii) binary classification of healthy controls versus headache type using a 3D ResNet-18; and (iii) biomarker extraction from the trained 3D ResNet-18. During the classification at the second step of our pipeline, we resolved two common issues in deep learning methods, limited training data and imbalanced samples from different categories, by incorporating a large public data set and resampling among the headache cohorts. Our method achieved the following classification accuracies when tested on independent test sets: (i) migraine versus healthy controls—75% accuracy, 66.7% sensitivity and 83.3% specificity; (2) acute post-traumatic headache versus healthy controls—75% accuracy, 66.7% sensitivity and 83.3% specificity; and (3) persistent post-traumatic headache versus healthy controls—91.7% accuracy, 100% sensitivity and 83.3% specificity. The most significant biomarkers identified by the classifier for migraine were caudate, caudal anterior cingulate, superior frontal, thalamus and ventral diencephalon. For acute post-traumatic headache, lateral occipital, cuneus, lingual, pericalcarine and superior parietal regions were identified as most significant biomarkers. Finally, for persistent post-traumatic headache, the most significant biomarkers were cerebellum, middle temporal, inferior temporal, inferior parietal and superior parietal. In conclusion, our study shows that the deep learning methods can automatically detect aberrations in the brain regions associated with different headache types. It does not require any human knowledge as input which significantly reduces human effort. It uncovers the great potential of deep learning methods for classification and automatic extraction of brain imaging–based biomarkers for these headache types.
The relevance of rich club regions for functional outcome post‐stroke is enhanced in women
Bonkhoff, Anna K. , Schirmer, Markus D. , Hong, Sung‐Min , Regenhardt, Robert W. , Donahue, Kathleen, Nardin, Marco, Etherton, Mark R. , Hancock, Brandon L., Mocking, Steven J. T. , McIntosh, Elissa C. , Donatti, Amanda , Heitsch, Laura , Jiménez-Conde, Jordi , Kittner, Steven J. , Levi, Christopher , Rosand, Jonathan, Schmidt, Reinhold , Sharma, Pankaj , Słowik, Agnieszka , Sousa, Alessandro , Stanne, Tara M. , Strbian, Daniel , Thijs, Vincent , Wassélius, Johan , Woo, Daniel , Zand, Ramin, McArdle, Patrick F. , Worrall, Bradford B. , Maguire, Jane , Wu, Ona , Rost, Natalia S. , Zand, Ramin , Strbian, Daniel , Regenhardt, Robert W , Wu, Ona , Zand, Ramin , Bretzner, Martin , Hong, Sungmin, Dalca, Adrian Vasile , Giese, Anne‐Katrin , Attia, John , Cole, John W. , Griessenauer, Christoph J. , Holmegaard, Lukas , Jood, Katarina , Lemmens, Robin , McDonough, Caitrin W. , Meschia, James F. , Phuah, Chia‐Ling , Ropele, Stefan , Rosand, Jonathan M. , Roquer, Jaume , Rundek, Tatjana , Sacco, Ralph L. , Tatlisumak, Turgut , Vagal, Achala , Jern, Christina , Lindgren, Arne G.

Mayo Clinic

Human Brain Mapping | November 28, 2022 | Volume: 44 | Issue: 4 | Pages: 1579-1592

10.1002/hbm.26159 | PMID 36440953 Get It

Abstract This study aimed to investigate the influence of stroke lesions in predefined highly interconnected (rich‐club) brain regions on functional outcome post‐stroke, determine their spatial specificity and explore the effects of biological sex on their relevance. We analyzed MRI data recorded at index stroke and ~3‐months modified Rankin Scale (mRS) data from patients with acute ischemic stroke enrolled in the multisite MRI‐GENIE study. Spatially normalized structural stroke lesions were parcellated into 108 atlas‐defined bilateral (sub)cortical brain regions. Unfavorable outcome (mRS > 2) was modeled in a Bayesian logistic regression framework. Effects of individual brain regions were captured as two compound effects for (i) six bilateral rich club and (ii) all further non‐rich club regions. In spatial specificity analyses, we randomized the split into “rich club” and “non‐rich club” regions and compared the effect of the actual rich club regions to the distribution of effects from 1000 combinations of six random regions. In sex‐specific analyses, we introduced an additional hierarchical level in our model structure to compare male and female‐specific rich club effects. A total of 822 patients (age: 64.7[15.0], 39% women) were analyzed. Rich club regions had substantial relevance in explaining unfavorable functional outcome (mean of posterior distribution: 0.08, area under the curve: 0.8). In particular, the rich club‐combination had a higher relevance than 98.4% of random constellations. Rich club regions were substantially more important in explaining long‐term outcome in women than in men. All in all, lesions in rich club regions were associated with increased odds of unfavorable outcome. These effects were spatially specific and more pronounced in women.
Lung-on-chip microdevices to foster pulmonary drug discovery
Sisodia, Yashi, Sayyed, Adil Ali , Jain, Meenakshi, Ali, Syed Ansar, Gondaliya, Piyush , Kalia, Kiran , Tekade, Rakesh Kumar , Ali Sayyed, Adil , Tekade, Rakesh Kumar , Shah, Komal

Mayo Clinic

Biomaterials Science | November 28, 2022 | Volume: 11 | Issue: 3 | Pages: 777-790

10.1039/d2bm00951j | PMID 36537540 Get It

Fostering pulmonary research for managing pulmonary threat requires a potential alternative approach mimicking the in vivo complexities. This review expounds on lung-on-chip microfluidic simulator devices to foster pulmonary drug discovery and personalized medicine.